SVA [SINOVAC BIOTECH] SC 13G/A: (Original Filing)
[CUSIP No. P8696W104 13G Page 2 of 9 Pages 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sanjay Motwani 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*]
SVA [SINOVAC BIOTECH] SC 13G/A: CUSIP No. P8696W104 13G Page 2 of 9
[CUSIP No. P8696W104 13G Page 2 of 9 Pages 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sanjay Motwani 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives China’s First Influenza A (H1N1) Vaccine
[Sinovac Receives China's First Influenza A (H1N1) Vaccine Order BEIJING, June 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that the Company received the first order in China to supply its influenza A (H1N1) vaccine to the Beijing government. The initial order consists of 4 million doses and] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE
[SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: Sinovac to Host Conference Call to Report 2009
[Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR
[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]
